a public good project by the
Synthesis
Company
of California

© 2026

Lan‐Ping Xu | doi.page

0 works0 citations0 h-index

Lan‐Ping Xu

Peking University(CN)National Clinical Research Center for Digestive Diseases(CN)Peking University People's Hospital(CN)National Clinical Research(US)Institute of Hematology & Blood Diseases Hospital(CN)

Publications by Year

Research Areas

Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Immune Cell Function and Interaction, T-cell and B-cell Immunology

Most-Cited Works

→ Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation(2005)510 cited
→ Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation(2015)21 cited
→ Metagenomic Next-generation Sequencing Compared With Blood Culture as First-line Diagnostic Method for Bloodstream Infection in Hematologic Patients With Febrile Neutropenia: A Multicenter, Prospective Study(2025)4 cited
→ Comparison of outcomes between haploidentical and matched related donors for chronic myelomonocytic leukemia: A multicenter real‐world study(2025)3 cited
→ Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T‐cell acute lymphoblastic leukaemia(2025)2 cited

→ Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia(2025)

1 cited

→ Peritransplant lysine methyltransferase 2a–rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia(2025)

→ Cerebrospinal fluid profile associated with the incidence and outcomes of patients with chronic graft-versus-host disease after haploidentical hematopoietic stem cell transplantation(2025)

→ PD-1 inhibitor in patients with minimal residual disease who failed donor lymphocyte infusion or interferon after allogeneic haematopoietic stem cell transplantation.(2025)

→ Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia(2024)